Clinical trial · Observational
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer.
NCT05594082CI-TRIAL-00065278unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this trial is to explore the real-world effectiveness and poteintial predictors in Chinese metastatic breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trastuzumab Deruxtecan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- progression-free survival
Secondary outcomes (4)
- measure
- ORR
- timeFrame
- 6 weeks
- description
- Overall Response Rate
- measure
- CBR
- timeFrame
- 6 weeks
- description
- Clinical benefit Rates
- measure
- OS
- timeFrame
- 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Plan to receive or has received Trastuzumab Deruxtecan monotherapy 4. Available medical history. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or breast-breeding
References
Publications (0)
Data not yet available
No reference posted for this study.